The SHELTER study also exhibited a high disease control rate in HCC patients treated by an HDACi, resminostat, and sorafenib [30], capable of inducing MICA expression [2] and suppressing ADAM9-mediated mMICA shedding [11], respectively, suggesting chemoimmunotherapeutic effects [31]. This evidence concerns the gene ADAM9 and hepatocellular carcinoma.